Drug: Lipitor
Company: Pfizer
Total spend Q1, 2012: $44.5 million
Total spend Q1, 2011: $71.9 million
Watch the TV commercial here >>

Lipitor lost patent protection in November, and while the company made some efforts to hold onto market share, it is clear from the reduced ad spend numbers that Lipitor has also lost its luster for Pfizer ($PFE). The company has been quietly winding down its marketing of the cholesterol fighter as generics makers have stripped it of sales. In the first quarter, Lipitor not only lost its hold on first place as the top selling drug--that honor went to Bristol-Myers Squibb's ($BMY) Plavix--it fell all the way to 14th place with $841 million in sales, surpassed even by its own generic copycats, which brought in $950 million.


Suggested Articles

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.